Clinical Significance of Serum Adenosine Deaminase Levels in Breast Cancer Patients

Abstract

Objective: To compare serum adenosine deaminase (ADA) levels in untreated and treated cases of breast cancer patients. Study Design: It was an Analytical, observational study. Place and Duration of study: The study was carried out in the Department of Biochemistry, Islamic international Medical College in collaboration with Department of Surgery, Holy Family Hospital, Rawalpindi during one year period from April 2017 to March 2018. Materials and Method: Total 150 subjects were selected for the study using convenient non probability sampling technique. Selection criteria for patients were both untreated and treated cases of breast cancer. Selection criteria for controls were healthy individual without having any malignancy and all the diseases in which adenosine deaminase is raised. Out of total 150 subjects, we took 70 controls and 80 cases. Of 80 cases, 44 were untreated and 36 were treated breast cancer patients. Serum adenosine deaminase levels of both controls and cases were measured and entered into SPSS version 21 for analysis. Descriptive data were given in the form of mean ± standard deviation (SD). “Independent t test” was applied and “p” values less than 0.05 were considered statistically significant. Results: Mean of serum adenosine deaminase level was compared among controls and untreated cases. It was found that serum ADA levels were high in untreated cases as compared to controls (17.75 ± 4.17 VS 14.92 ± 3.73) with p-value 0.001. Mean of serum ADA levels were also compared among untreated and treated cases. It was found that serum ADA levels were markedly low in treated cases as compared to untreated cases (13.18 ± 4.18 VS 17.75±4.17) with p-value ˂0.0001. Conclusion: It is concluded that serum adenosine deaminase levels are significantly raised in female patients of breast cancer; however these levels get lowered after treatment such as chemotherapy, radiotherapy, hormonal therapy and surgical excision.

Keywords

• adenosine deaminase (ada), breast cancer, malignancy, mirna, tumor grades.